Last reviewed · How we verify
NCT06137950
Interferon Alpha Therapy for Cervical CINI and HPV Infection
Phase 1 trial testing gel Interferon arm in Cervical Dysplasia in 60 participants. Completed in 31 March 2025.
15 November 2024
Quick facts
| Lead sponsor | Mongolian National University of Medical Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 7 November 2023 |
| Primary completion | 15 November 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Mongolia |
Drugs / interventions tested
- gel Interferon arm — full drug profile →
- gel Interferon and interferon suppository arm — full drug profile →
Conditions studied
- Cervical Dysplasia — all drugs for Cervical Dysplasia →
- HPV Infection — all drugs for HPV Infection →
Sponsor
Mongolian National University of Medical Sciences
Who can join
Adults 20 to 40, female only, with Cervical Dysplasia or HPV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. During the years pap smear analysis of implemented in all rural areas and clinicians, lab technicians have been taught for the cervical cancer screening. However, the project has finished in 2015 and the rural and district hospitals has lost the trained professionals. Still the cervical cancer is in second place after liver cancer in women. The purpose of the study is to identify the type of HPV genotype and to treat the HPV infection by local interferon α2b. Materials and methods: HPV positive patients will be enrolled to the study. HPV genotype will be determined by the PCR in laboratory. Pap smear will be taken and staged by the CIN. Pathological tissue will be taken under colposcopy with acetic acid test. Follow up visit will be done on 10th, 30th days of the treatment. At the end of 90th days of treatment, pap and histology test will be repeated and CIN regression or viral eradication will be evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06137950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Dysplasia
Currently open trials in the same condition.
- NCT05640700 — Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia · recruiting
- NCT06452004 — Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) · NA · active not recruiting
- NCT05606133 — Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers · NA · recruiting
- NCT05774561 — Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring · recruiting
- NCT05051722 — Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · recruiting
Other Mongolian National University of Medical Sciences trials
Trials by the same sponsor.
- NCT06132542 — Autologous ADMSC Transplantation in Patients With POI · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06137950 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mongolian National University of Medical Sciences
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing